Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Meta Expands AI Training With Employee Activity Tracking Tools 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
IRVINE, Calif., May 22, 2017 -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that management will present at two upcoming investor conferences:
- B. Riley & Co.’s 18th Annual Investor Conference on Thursday, May 25, at 11:00 a.m. Pacific time. The conference is being held at the Loews Santa Monica Beach Hotel.
- 7th Annual LD Micro Invitational on Tuesday, June 6, at 3:00 p.m. Pacific time. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.
About CombiMatrix Corporation
CombiMatrix Corporation provides sophisticated molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. Our testing focuses on advanced technologies, including single nucleotide polymorphism chromosomal microarray analysis, next generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624
Investor Contact:
LHA
Jody Cain
(310) 691-7100
[email protected]
